Illuccix

Gozetotide, the active ingredient in Illuccix, is an investigational compound presented as an intravenous formulation for clinical use. It is being studied for potential therapeutic applications in various disease areas, though specific approved uses have not been established.

GNH USA supplies Illuccix as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres, pharmacies and clinics worldwide.

Illuccix (gozetotide) is currently under clinical investigation and has not received regulatory approval for specific therapeutic indications.

- No approved indications: the product remains investigational pending further clinical data.

Adverse reactions associated with Illuccix have not been fully characterized in publicly available sources.

Common Side Effects: - Data not available: specific common adverse events have not been reported.

Serious or Rare Side Effects: - Data not available: serious or rare adverse events have not been reported.

When handling Illuccix, consider the following safety and handling measures. - Administration setting: ensure intravenous administration is performed by qualified healthcare professionals. - Monitoring: observe patients for any unexpected reactions during and after infusion. - Compatibility: verify compatibility with IV fluids and infusion sets before use. - Waste disposal: follow local regulations for disposal of biologic waste. - Storage: Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Potential drug interactions for Illuccix have not been established in the literature.

Major Interactions (Avoid): - Data not available: no major interactions have been identified.

Moderate Interactions (Monitor Closely): - Data not available: no moderate interactions have been identified.